Decitabine
Generic Name: decitabine
Brand Names:
Decitabine
Decitabine is a nucleoside metabolic inhibitor supplied as a sterile, white to off-white lyophilized powder containing 50 mg per vial with inactive ingredients including potassium phosphate and sodium hydroxide.
Overview
Decitabine is a nucleoside metabolic inhibitor supplied as a sterile, white to off-white lyophilized powder containing 50 mg per vial with inactive ingredients including potassium phosphate and sodium hydroxide.
Uses
Treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated varieties, across all French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Dosage
Two options available: (1) 15 mg/m2 IV infusion over 3 hours every 8 hours for 3 days, repeated every 6 weeks; or (2) 20 mg/m2 IV infusion over 1 hour daily for 5 days, repeated every 4 weeks. Minimum 4 cycles recommended.
Side Effects
Most common adverse reactions (greater than 50%): neutropenia, thrombocytopenia, anemia, and pyrexia. Grade 3-4 neutropenia occurred in 87% of patients; febrile neutropenia in 23%.
Interactions
In vitro studies suggest decitabine is unlikely to inhibit or induce cytochrome P450 enzymes, and plasma protein binding is negligible, making interactions unlikely.
Warnings
Fatal myelosuppression occurs in treated patients. Complete blood counts required at baseline and prior to each cycle. Embryo-fetal toxicity: can cause fetal harm; females must use contraception for 6 months post-treatment; males for 3 months.
Pregnancy
Based on human data and animal studies, decitabine can cause fetal harm including malformations and embryo-fetal lethality at doses approximately 7% of recommended human dose.
Frequently Asked Questions
What is Decitabine used for?▼
Treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated varieties, across all French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
What are the side effects of Decitabine?▼
Most common adverse reactions (greater than 50%): neutropenia, thrombocytopenia, anemia, and pyrexia. Grade 3-4 neutropenia occurred in 87% of patients; febrile neutropenia in 23%.
Can I take Decitabine during pregnancy?▼
Based on human data and animal studies, decitabine can cause fetal harm including malformations and embryo-fetal lethality at doses approximately 7% of recommended human dose.
What are the important warnings for Decitabine?▼
Fatal myelosuppression occurs in treated patients. Complete blood counts required at baseline and prior to each cycle. Embryo-fetal toxicity: can cause fetal harm; females must use contraception for 6 months post-treatment; males for 3 months.
Related Medications
Verapamil Hci
verapamil hci
DESCRIPTION Verapamil hydrochloride is a calcium antagonist or slow-channel inhibitor available as a sterile solution for intravenous injection in 5-mg (2 ml) and 10-mg (4 ml) vials. Each form contains Verapamil HCl 2.5 mg/ml and sodium chloride 8.5 mg/ml in water for injection. Hydrochloric acid and/or sodium hydroxide is used for pH adjustment. The pH of the solution is between 4.1 and 6.0.
Malus Pumila, Flos
malus pumila, flos
INDICATIONS: For temporary relief of feeling unclean or infected, self-disgust, and getting bogged down in detail.
Dextrose And Sodium Chloride
dextrose and sodium chloride
11 DESCRIPTION Dextrose and Sodium Chloride Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in single-dose containers for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in Table 1 . Table 1. Size (mL) Composition (g/L) Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.